NCT06710821View on ClinicalTrials.gov

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Solid Tumor Cancer
Interventions
DRUG

Liposomal irinotecan in combination with vincristine and temozolomide

Vincristine: 1.5 mg/m², iv, d1. l Temozolomide 150 mg/m²/d, iv drip, d1-5. l Irinotecan liposomal RP dose, iv infusion over 90 min, d1. Q3W, 4 cycles expected until disease progression or intolerable toxicity occurs

All Listed Sponsors
lead

Yizhuo Zhang

OTHER

NCT06710821 - Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors | Biotech Hunter | Biotech Hunter